Major outcome group 3 (early angular outcome)b · 93 participants (van Rijssen 2012a)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · palliative participants with esophageal and GE‐junction carcinoma
Summary of findings table: chemotherapy or targeted therapy agent(s)… leads to lower overall survival compared with control intervention alone (high certainty).
1 finding from 1 review
Progression‐free survival · palliative participants with esophageal and GE‐junction carcinoma
Summary of findings table: chemotherapy or targeted therapy agent(s)… probably leads to lower progression‐free survival compared with control intervention alone (moderate certainty).
1 finding from 1 review
Toxicity · palliative participants with esophageal and GE‐junction carcinoma
It is very uncertain whether summary of findings table: chemotherapy or targeted therapy agent(s)… changes toxicity compared with control intervention alone (very low certainty).
1 finding from 1 review
Quality of life · palliative participants with esophageal and GE‐junction carcinoma
1 finding from 1 review
Outcomesa · 125 hands in 121 participants with Dupuytren's disease of the fingers for early outcomes (van Rijssen 2006)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
DASH hand function score at 3 months Major outcome group 1 (hand function) (scores between 0 and 100, where 0 represents no impairment in hand function and 100 represents maximum impairment in hand function) · 125 hands in 121 participants with Dupuytren's disease of the fingers for early outcomes (van Rijssen 2006)
1 finding from 1 review
Major outcome group 2 (patient satisfaction) · 125 hands in 121 participants with Dupuytren's disease of the fingers for early outcomes (van Rijssen 2006)
1 finding from 1 review
Early angular outcome at 6 weeks for Tubiana grade I disease (total passive extension deficit (TPED) of the MCPJ, PIPJ and DIPJ for preoperative contractures with a TPED of 0 to 45 degrees) Early angular outcome at 6 weeks for Tubiana grade II dis... · 125 hands in 121 participants with Dupuytren's disease of the fingers for early outcomes (van Rijssen 2006)
1 finding from 1 review
Recurrence · 125 hands in 121 participants with Dupuytren's disease of the fingers for early outcomes (van Rijssen 2006)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Paraesthesia · 125 hands in 121 participants with Dupuytren's disease of the fingers for early outcomes (van Rijssen 2006)
1 finding from 1 review
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
It is very uncertain whether summary of findings table ‐ Contact immunotherapy (diphencyprone or… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (very low certainty).
1 finding from 1 review
Incidence of serious adverse events ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
It is very uncertain whether summary of findings table ‐ Contact immunotherapy (diphencyprone or… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with hair growth stimulants (minoxidil) (very low certainty).
1 finding from 1 review
Incidence of serious adverse events ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Food and fluid intake, measured as amount of served food eaten (percentage, · people with dementia
1 finding from 1 review